[{"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-001", "question": "A 68-year-old man with a history of severe COPD (FEV1 35% predicted) and chronic hypercapnia (baseline PaCO2 55 mmHg) presents with acute-on-chronic hypercapnic respiratory failure requiring non-invasive ventilation. After 48 hours of improvement, his arterial blood gas shows pH 7.36, PaCO2 48 mmHg, PaO2 85 mmHg on 2 L/min nasal cannula. He is alert and comfortable. The next most appropriate step in management is:", "options": ["Gradually wean and discontinue supplemental oxygen to target a PaO2 of 55-60 mmHg", "Continue current oxygen therapy and plan for discharge home with home oxygen", "Increase oxygen flow to achieve a PaO2 > 88 mmHg", "Obtain a venous blood gas to confirm the arterial values", "Initiate acetazolamide 250 mg twice daily to accelerate renal compensation"], "answer": "A", "answer_index": 0, "explanation": "In patients with chronic hypercapnia, the hypoxic drive is a primary respiratory stimulus. Over-oxygenation can suppress this drive, leading to worsening hypercapnia and acidosis. The target PaO2 is 55-60 mmHg or SpO2 88-92%, which provides adequate oxygenation while minimizing the risk of CO2 retention. Increasing oxygen (C) is dangerous, and acetazolamide (E) is not indicated in acute-on-chronic respiratory failure as it can worsen acidosis by inhibiting compensatory metabolic alkalosis.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is a 68-year-old man with severe COPD and chronic hypercapnia who has recovered from an acute-on-chronic hypercapnic respiratory failure requiring non-invasive ventilation. His current arterial blood gas (ABG) shows:\n- pH: 7.36 (normal range: 7.35-7.45) - This indicates a compensated or normal acid-base balance.\n- PaCO2: 48 mmHg (baseline PaCO2 55 mmHg) - This is elevated but improved from his chronic baseline and reflects resolution of acute hypercapnic respiratory failure. An elevated PaCO2 is expected in severe COPD.\n- PaO2: 85 mmHg on 2 L/min nasal cannula - This indicates adequate oxygenation.\n\nThe patient is alert and comfortable. The question asks for the next most appropriate step in management.\n\nLet's analyze the options:\nA. Gradually wean and discontinue supplemental oxygen to target a PaO2 of 55-60 mmHg: In patients with COPD and chronic hypercapnia, oxygen therapy should be carefully titrated. The goal is typically to maintain oxygen saturation (SpO2) between 88-92%, which corresponds to a PaO2 of 55-60 mmHg. Giving higher levels of oxygen can suppress the respiratory drive, leading to hypoventilation and worsening hypercapnia. The patient's current PaO2 of 85 mmHg on 2 L/min of oxygen is significantly higher than the target range. Therefore, weaning the supplemental oxygen is the most appropriate next step. The phrasing \"to target a PaO2 of 55-60 mmHg\" refers to the safe range if supplemental oxygen is still required after weaning, or as a goal to achieve during oxygen titration.\n\nB. Continue current oxygen therapy and plan for discharge home with home oxygen: While the patient may eventually need home oxygen, his current PaO2 of 85 mmHg on 2 L/min suggests he may be receiving more oxygen than necessary. It is prudent to attempt to wean his oxygen first to assess his true baseline requirement before planning for home oxygen.\n\nC. Increase oxygen flow to achieve a PaO2 > 88 mmHg: This is contraindicated in patients with COPD and chronic hypercapnia, as it can lead to excessive oxygen administration, suppress respiratory drive, and worsen hypercapnia.\n\nD. Obtain a venous blood gas to confirm the arterial values: The patient is alert, comfortable, and has an ABG that shows improvement. There is no clinical indication to obtain a venous blood gas for confirmation of arterial values in this scenario.\n\nE. Initiate acetazolamide 250 mg twice daily to accelerate renal compensation: Acetazolamide is used to promote diuresis and can help correct chronic respiratory acidosis by stimulating metabolic compensation (inducing a metabolic acidosis). However, the patient's pH is 7.36, which is within the normal range, and his PaCO2 has improved. There is no indication for acetazolamide at this time.\n\nBased on the above analysis, the most appropriate next step is to gradually wean the supplemental oxygen given the current PaO2 is higher than the recommended target for COPD patients at risk of hypercapnic respiratory failure.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-002", "question": "A 45-year-old woman with a history of recurrent calcium oxalate kidney stones presents with acute pancreatitis. Lipase is 1200 U/L, calcium 11.8 mg/dL, PTH 85 pg/mL (normal 10-65). She is not on lithium or thiazides. A pancreatic protocol CT shows diffuse gland enlargement but no necrosis or ductal dilation. The most likely underlying etiology of her pancreatitis is:", "options": ["Primary hyperparathyroidism due to parathyroid adenoma", "Autoimmune pancreatitis (IgG4-related disease)", "Hereditary pancreatitis due to PRSS1 mutation", "Hypertriglyceridemia-induced pancreatitis", "Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome)"], "answer": "A", "answer_index": 0, "explanation": "The triad of hypercalcemia, elevated PTH, and recurrent calcium oxalate stones is classic for primary hyperparathyroidism. Hypercalcemia is a known, though uncommon, cause of pancreatitis. The elevated PTH confirms primary hyperparathyroidism, not secondary causes. While hypertriglyceridemia (D) can cause pancreatitis, it doesn't explain the hypercalcemia and elevated PTH. Gastrinoma (E) is associated with ulcers and diarrhea, not typically hypercalcemia and stones.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "A 45-year-old woman presents with acute pancreatitis. Her lipase is elevated. Key laboratory findings include elevated calcium (11.8 mg/dL) and elevated Parathyroid Hormone (PTH) (85 pg/mL), with normal levels for calcium being around 8.5-10.5 mg/dL and normal PTH being 10-65 pg/mL. The patient also has a history of recurrent calcium oxalate kidney stones, which is often associated with hypercalcemia. She is not taking medications known to cause hypercalcemia like lithium or thiazides. The CT scan shows diffuse pancreatic enlargement without necrosis or ductal dilation.\n\nLet's evaluate the options:\n\nA. Primary hyperparathyroidism due to parathyroid adenoma: Elevated calcium and elevated PTH are classic signs of primary hyperparathyroidism. Hypercalcemia is a known risk factor for acute pancreatitis. The history of calcium oxalate kidney stones further supports a diagnosis of hyperparathyroidism, as it leads to increased urinary calcium excretion. This option aligns perfectly with all the presented findings.\n\nB. Autoimmune pancreatitis (IgG4-related disease): While autoimmune pancreatitis can cause diffuse pancreatic enlargement, the laboratory findings of hypercalcemia and elevated PTH are not typical features of this condition.\n\nC. Hereditary pancreatitis due to PRSS1 mutation: Hereditary pancreatitis usually presents earlier in life and is characterized by recurrent episodes of pancreatitis, often without clear metabolic causes like hypercalcemia. Given the strong metabolic findings, this is less likely.\n\nD. Hypertriglyceridemia-induced pancreatitis: Hypertriglyceridemia is a common cause of pancreatitis, but it requires very high triglyceride levels (typically >1000 mg/dL). There is no mention of triglyceride levels in the case, and the dominant abnormal findings relate to calcium and PTH metabolism.\n\nE. Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome): Gastrinomas are associated with Zollinger-Ellison syndrome and can lead to pancreatitis, but they do not directly cause hypercalcemia or elevated PTH. While gastrinomas are part of MEN1 syndrome which can include parathyroid adenomas, the primary issue presented here is clearly hypercalcemia with confirmed hyperparathyroidism.\n\nBased on the elevated calcium, elevated PTH, and history of calcium oxalate stones, primary hyperparathyroidism is the most likely underlying cause of her acute pancreatitis.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-003", "question": "A 32-year-old woman presents with 3 weeks of progressive dyspnea and fatigue. Echocardiogram shows a large pericardial effusion with diastolic right atrial and right ventricular collapse. Right heart catheterization reveals equalization of diastolic pressures (RA 18, RV 18, PA 18/20, PCWP 18 mmHg). After pericardiocentesis of 800 mL of serosanguinous fluid, hemodynamics improve. Cytology is negative. Two days later, she develops recurrent dyspnea. Repeat echo shows reaccumulation of the effusion. The most appropriate definitive management is:", "options": ["Repeat pericardiocentesis and initiate colchicine", "Surgical creation of a pericardial window via subxiphoid approach", "Initiation of high-dose prednisone for suspected autoimmune pericarditis", "Pericardiectomy via left thoracotomy", "Intrapericardial instillation of bleomycin"], "answer": "B", "answer_index": 1, "explanation": "Recurrent symptomatic pericardial effusion with tamponade physiology, especially when cytology is negative (ruling out malignancy requiring specific therapy), is a clear indication for a definitive surgical procedure to prevent reaccumulation. A surgical pericardial window (subxiphoid or video-assisted) allows for drainage and biopsy. Pericardiectomy (D) is reserved for constrictive pericarditis. Steroids (C) are for inflammatory causes but are not definitive for recurrent effusion. Intrapericardial chemotherapy (E) is for malignant effusions.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms and hemodynamic findings consistent with cardiac tamponade, caused by a large pericardial effusion. Initial pericardiocentesis provided temporary relief, but the effusion has rapidly reaccumulated, leading to recurrent symptoms. This indicates a need for a more definitive solution to manage the recurrent large effusion and prevent tamponade.\n\nLet's evaluate the options:\nA. Repeat pericardiocentesis and initiate colchicine: While colchicine is effective in preventing recurrences of pericarditis, repeat pericardiocentesis is ultimately a temporizing measure for rapidly accumulating effusions causing tamponade. It doesn't provide a definitive solution for continuous drainage.\nB. Surgical creation of a pericardial window via subxiphoid approach: This procedure provides a more permanent drainage pathway for the pericardial fluid, preventing reaccumulation into the pericardial space and relieving the pressure on the heart. It is a standard and effective treatment for recurrent symptomatic pericardial effusions causing tamponade, especially when medical management or simple drainage is insufficient.\nC. Initiation of high-dose prednisone for suspected autoimmune pericarditis: While autoimmune pericarditis is a possibility, empirical treatment with steroids might not be sufficient to manage a large, rapidly reaccumulating effusion causing tamponade. A definitive drainage procedure is often prioritized in such cases, and steroids may be used adjunctively or if the underlying cause is definitively identified as inflammatory and responsive to steroids.\nD. Pericardiectomy via left thoracotomy: Pericardiectomy is a more extensive surgery, typically reserved for chronic constrictive pericarditis or very refractory cases of recurrent effusive pericarditis. It is not the first-line definitive management for a 32-year-old with subacute recurrent tamponade.\nE. Intrapericardial instillation of bleomycin: This is a sclerosing agent used for malignant effusions or effusions refractory to other treatments. It is not typically the initial definitive management for a non-malignant, rapidly recurrent effusion.\n\nGiven the rapid reaccumulation of a large pericardial effusion causing tamponade physiology, a surgical pericardial window is the most appropriate definitive management to ensure adequate and continuous drainage. The subxiphoid approach is a minimally invasive technique for this.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-004", "question": "A 70-year-old man with atrial fibrillation on apixaban (non-valvular) presents with acute onset of right-sided weakness and aphasia 4 hours after symptom onset. NIHSS is 15. CT head shows no hemorrhage. He is not a candidate for IV tPA due to anticoagulation. CT angiography shows a left M1 MCA occlusion. The most appropriate acute intervention is:", "options": ["Administer IV tPA after checking an INR and anti-Xa level", "Proceed directly to mechanical thrombectomy without thrombolysis", "Administer IV protamine to reverse apixaban, then give IV tPA", "Administer andexanet alfa, then give IV tPA", "Initiate IV heparin drip and observe for neurological improvement"], "answer": "B", "answer_index": 1, "explanation": "For patients with acute ischemic stroke and large vessel occlusion (LVO) who are not candidates for IV tPA, mechanical thrombectomy is the standard of care if performed within 24 hours of last known well and meeting other criteria (like NIHSS â‰¥6). Direct thrombectomy is non-inferior to bridging therapy (tPA + thrombectomy). Reversing anticoagulation to give tPA (C, D) delays definitive therapy and adds bleeding risk. Giving tPA on top of therapeutic anticoagulation (A) is contraindicated.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "SB: The patient presents with an acute ischemic stroke with a confirmed large vessel occlusion (LVO) in the left M1 MCA. The NIHSS of 15 indicates a moderate to severe stroke. The CT head shows no hemorrhage, making reperfusion therapies possible if not for contraindications. The patient is on apixaban, a direct oral anticoagulant (DOAC), and the vignette explicitly states he is \"not a candidate for IV tPA due to anticoagulation.\" This contraindication typically arises because the presence of the anticoagulant (especially within the 48 hours prior to symptom onset) increases the risk of hemorrhagic transformation after thrombolysis.\n\nLet's analyze the options:\nA. Administer IV tPA after checking an INR and anti-Xa level: Checking INR is irrelevant for apixaban. While an anti-Xa level can provide information about apixaban levels, the vignette states he is not a candidate for IV tPA due to anticoagulation, implying this decision has already been made and is not easily reversible in the acute setting for tPA administration.\nB. Proceed directly to mechanical thrombectomy without thrombolysis: Mechanical thrombectomy is the standard of care for patients with acute ischemic stroke due to LVO, especially when IV tPA is contraindicated or has failed. This option directly addresses the identified cause of stroke (LVO) with an effective reperfusion strategy.\nC. Administer IV protamine to reverse apixaban, then give IV tPA: Protamine sulfate is the reversal agent for unfractionated heparin and low molecular weight heparin, not for direct factor Xa inhibitors like apixaban. This option is pharmacologically incorrect.\nD. Administer andexanet alfa, then give IV tPA: Andexanet alfa is the specific reversal agent for apixaban. Theoretically, reversing apixaban could make the patient a candidate for IV tPA. However, the vignette states he is *not a candidate* for tPA. In the setting of a confirmed LVO and contraindication to tPA, mechanical thrombectomy is the primary reperfusion modality. While some centers might consider reversal followed by tPA in specific circumstances, proceeding *directly* to thrombectomy for an LVO when tPA is contraindicated is a more straightforward and often preferred approach, especially given that thrombectomy can be performed with or without preceding IV tPA. The decision to proceed directly to thrombectomy bypasses the complexities and potential delays of reversal if the primary goal is reperfusion of the LVO.\nE. Initiate IV heparin drip and observe for neurological improvement: Heparin is an anticoagulant and not a treatment for acute ischemic stroke reperfusion. Starting heparin acutely would not resolve the occlusion and could increase bleeding risk.\n\nConsidering the patient has a confirmed LVO and is stated to be not a candidate for IV tPA, mechanical thrombectomy is the most appropriate and direct intervention to restore blood flow and improve neurological outcomes.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-005", "question": "A 55-year-old man with alcoholic cirrhosis (Child-Pugh B) is admitted with hepatic encephalopathy. He is started on lactulose. On day 3, he develops acute kidney injury. Serum sodium is 122 mEq/L (down from 128 on admission), creatinine 2.4 mg/dL (baseline 0.9), and he is clinically envolemic. Urine sodium is <10 mEq/L, urine osmolality 550 mOsm/kg. The most likely cause of his hyponatremia is:", "options": ["Syndrome of inappropriate antidiuretic hormone secretion (SIADH)", "Acute tubular necrosis from sepsis", "Hepatorenal syndrome type 1", "Pseudohyponatremia from hypertriglyceridemia", "Hyponatremia due to lactulose-induced diarrhea"], "answer": "E", "answer_index": 4, "explanation": "Lactulose causes an osmotic diarrhea, leading to loss of sodium and water, but relatively more water loss, resulting in hypertonic hyponatremia. The clinical picture (envolemic, high urine osmolality, low urine sodium) is consistent with volume depletion from GI losses, not SIADH (which has inappropriately high urine sodium). Hepatorenal syndrome (C) is characterized by low urine sodium but typically occurs in the setting of avid sodium retention and ascites, not acute diarrhea. ATN (B) would have high urine sodium.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has alcoholic cirrhosis (Child-Pugh B), a condition associated with hemodynamic disturbances that can lead to hepatorenal syndrome (HRS). He presents with acute kidney injury (creatinine 2.4 mg/dL from baseline 0.9), hyponatremia (serum sodium 122 mEq/L), and a clinically euvolemic state. Crucially, his urine sodium is <10 mEq/L and his urine osmolality is high at 550 mOsm/kg.\n\nLet's evaluate the options:\nA. Syndrome of inappropriate antidiuretic hormone secretion (SIADH): While SIADH can cause hyponatremia with inappropriately concentrated urine, it is typically characterized by a urine sodium >20 mEq/L (unless the patient is on a very low sodium diet or diuretics). The low urine sodium (<10 mEq/L) makes typical SIADH less likely.\n\nB. Acute tubular necrosis from sepsis: Sepsis can cause AKI. However, ATN is usually associated with impaired sodium reabsorption, leading to a urine sodium >40 mEq/L and a low urine osmolality (typically <350 mOsm/kg). This patient's findings (urine sodium <10 mEq/L, urine osmolality 550 mOsm/kg) are inconsistent with ATN.\n\nC. Hepatorenal syndrome type 1 (HRS-1): This condition is a form of functional renal failure that occurs in patients with advanced cirrhosis and ascites. It is characterized by severe renal vasoconstriction resulting in AKI, sodium and water retention, and hyponatremia. Key diagnostic features include low urine sodium (<10 mEq/L), high urine osmolality (reflecting maximal water reabsorption), and impaired renal function (elevated creatinine). The patient's history of cirrhosis, development of AKI, hyponatremia, low urine sodium, and high urine osmolality are classic findings for HRS-1. The clinically euvolemic state does not exclude HRS, as the primary issue is circulatory dysfunction.\n\nD. Pseudohyponatremia from hypertriglyceridemia: This is a laboratory artifact caused by a high concentration of lipids in the serum that displaces water, leading to a falsely low measured sodium. There is no information provided to suggest hypertriglyceridemia.\n\nE. Hyponatremia due to lactulose-induced diarrhea: While lactulose can cause diarrhea, leading to fluid and electrolyte losses and potentially hyponatremia and AKI, the patient is described as clinically euvolemic. If diarrhea were the primary cause of AKI and hyponatremia, hypovolemia would be expected. Furthermore, the extremely low urine sodium (<10 mEq/L) is highly suggestive of severe renal sodium conservation due to circulatory dysfunction (as seen in HRS) rather than simply volume depletion from diarrhea.\n\nConsidering all the findings, hepatorenal syndrome type 1 is the most likely cause of the patient's hyponatremia and acute kidney injury.\n\nThe answer is (C)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-006", "question": "A 28-year-old pregnant woman at 32 weeks gestation is admitted for severe preeclampsia with BP 170/110 mmHg. She is started on IV magnesium sulfate for seizure prophylaxis and IV labetalol for blood pressure control. One hour after initiation of magnesium, she becomes somnolent, with loss of deep tendon reflexes. Respiratory rate is 8 breaths/min. Serum magnesium level is 9.2 mg/dL. After securing the airway, the most specific immediate treatment is:", "options": ["IV administration of 10% calcium gluconate 1 gram over 10 minutes", "IV administration of furosemide 40 mg to enhance renal excretion", "Immediate hemodialysis", "Discontinuation of magnesium sulfate and administration of IV levothyroxine", "IV administration of pyridostigmine 2 mg"], "answer": "A", "answer_index": 0, "explanation": "Calcium gluconate is the direct antagonist to the life-threatening cardiac and neuromuscular effects of hypermagnesemia. It stabilizes cardiac membranes and reverses respiratory depression caused by magnesium. Furosemide (B) promotes excretion but is not immediate. Dialysis (C) is for severe cases with renal failure but is not the first step after airway management. Pyridostigmine (E) is for myasthenia, not magnesium toxicity.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient is presenting with signs and symptoms of magnesium sulfate toxicity, including somnolence, loss of deep tendon reflexes, and respiratory depression (respiratory rate 8 breaths/min). Her serum magnesium level of 9.2 mg/dL is elevated and consistent with these findings. Magnesium toxicity affects neuromuscular transmission and can lead to central nervous system depression, hypotension, bradycardia, hyporeflexia, muscle weakness, and respiratory arrest.\n\nAfter securing the airway, the immediate and most specific treatment for symptomatic magnesium toxicity is the administration of calcium. Calcium acts as an antagonist to magnesium at the neuromuscular junction, counteracting the depressant effects of excess magnesium.\n\nLet's evaluate the options:\nA. IV administration of 10% calcium gluconate 1 gram over 10 minutes: This is the standard antidote for magnesium toxicity. Calcium gluconate or calcium chloride reverses the neuromuscular and cardiac effects of hypermagnesemia.\nB. IV administration of furosemide 40 mg to enhance renal excretion: While impaired renal excretion contributes to magnesium accumulation, furosemide does not directly antagonize the immediate toxic effects. It is a supportive measure but not the most specific immediate treatment for acute toxicity symptoms.\nC. Immediate hemodialysis: Hemodialysis is effective for severe, refractory magnesium toxicity, especially in patients with renal failure. However, it is a complex procedure and not the first-line or most specific *immediate* treatment when an antidote readily available.\nD. Discontinuation of magnesium sulfate and administration of IV levothyroxine: Discontinuation of magnesium is essential, but levothyroxine is thyroid hormone and is completely unrelated to magnesium toxicity treatment.\nE. IV administration of pyridostigmine 2 mg: Pyridostigmine is a cholinesterase inhibitor. While it enhances neuromuscular transmission, it is not the specific antidote for magnesium toxicity. Calcium is the specific antagonist.\n\nTherefore, IV calcium gluconate is the most specific immediate treatment following airway management.\n\nThe answer is A"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-007", "question": "A 62-year-old man with a history of asbestos exposure 30 years ago presents with unilateral right-sided pleural effusion. Thoracentesis reveals exudative fluid (by Light's criteria) with cytology positive for adenocarcinoma. PET-CT shows FDG-avid right pleural thickening and effusion, with no other distant metastases. The next best step in management is:", "options": ["Systemic chemotherapy with platinum-pemetrexed", "Pleurodesis followed by systemic chemotherapy", "Extrapleural pneumonectomy", "Pleurectomy/decortication followed by adjuvant chemoradiation", "Immunotherapy with pembrolizumab as first-line treatment"], "answer": "D", "answer_index": 3, "explanation": "This describes a likely diagnosis of malignant pleural mesothelioma (given asbestos exposure, unilateral effusion, pleural thickening). For resectable disease (stage I-III) in a fit patient, the standard of care is maximal cytoreductive surgery (pleurectomy/decortication) followed by adjuvant chemotherapy and possibly radiation. Extrapleural pneumonectomy (C) is a more radical, less commonly performed option. Systemic therapy alone (A) is for unresectable disease. Pleurodesis (B) is palliative.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a unilateral pleural effusion and thickening, positive cytology for adenocarcinoma, and a history of asbestos exposure. This clinical picture is highly suggestive of malignant pleural mesothelioma (MPM), an asbestos-related cancer of the pleura. The PET-CT shows FDG-avid disease confined to the pleura without distant metastases, suggesting potentially localized or resectable disease.\n\nLet's analyze the options:\n\nA.  Systemic chemotherapy with platinum-pemetrexed: This is the standard first-line treatment for unresectable MPM or as neoadjuvant therapy prior to surgery. However, if the disease is resectable, surgical intervention is typically a key component of the management strategy.\n\nB.  Pleurodesis followed by systemic chemotherapy: Pleurodesis is primarily a palliative procedure used to control symptomatic malignant effusions by obliterating the pleural space. It is not a curative treatment for the underlying malignancy itself.\n\nC.  Extrapleural pneumonectomy (EPP): EPP is a radical surgical procedure involving the removal of the affected lung, pleura, diaphragm, and pericardium. It is an option for carefully selected patients with early-stage (e.g., Stage I/II) MPM. However, it is a highly morbid surgery, and often Pleurectomy/decortication (P/D) is preferred when possible. Furthermore, surgery is typically part of a multimodal approach.\n\nD.  Pleurectomy/decortication (P/D) followed by adjuvant chemoradiation: P/D involves removing the parietal and visceral pleura, aiming for macroscopic debulking of tumor while preserving the lung. This is another surgical option for resectable MPM, often preferred over EPP due to lower morbidity. Multimodal therapy, including surgery followed by adjuvant chemotherapy and/or radiation, is the current standard of care for resectable MPM to improve survival outcomes. This option represents a comprehensive and appropriate management strategy for localized MPM.\n\nE.  Immunotherapy with pembrolizumab as first-line treatment: Immunotherapy, often pembrolizumab-based, is a standard first-line treatment for unresectable MPM, sometimes in combination with chemotherapy. However, similar to systemic chemotherapy alone, it is not typically the *next best step* if the disease is deemed potentially resectable by surgery.\n\nGiven the localized nature of the disease on PET-CT and the strong suspicion for MPM, a multimodal approach involving surgical resection followed by adjuvant therapy is the most appropriate management strategy. Option D outlines such an approach (P/D followed by adjuvant chemoradiation), which is tailored for potentially resectable MPM.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-008", "question": "A 40-year-old woman presents with palpitations, heat intolerance, and weight loss. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL (high). Thyroid ultrasound shows a 2 cm hypoechoic nodule in the right lobe. Radioactive iodine uptake scan shows diffusely increased uptake (45% at 24 hours) with a photopenic area corresponding to the nodule. The most likely diagnosis is:", "options": ["Graves' disease with a coexisting cold nodule", "Toxic multinodular goiter", "Subacute thyroiditis", "Factitious thyrotoxicosis", "Marine-Lenhart syndrome (Graves' disease with a functioning nodule)"], "answer": "A", "answer_index": 0, "explanation": "The diffusely increased uptake is diagnostic of Graves' disease. The photopenic ('cold') nodule within an area of diffusely high uptake indicates a non-functioning nodule, which raises concern for malignancy and requires FNA biopsy. Marine-Lenhart syndrome (E) is Graves' with a *functioning* (hot) nodule. Toxic MNG (B) would show multiple areas of increased uptake. Subacute thyroiditis (C) shows very low uptake.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with symptoms of hyperthyroidism (palpitations, heat intolerance, weight loss) supported by laboratory findings of suppressed TSH (<0.01 mIU/L) and elevated free T4 (3.2 ng/dL). These findings confirm thyrotoxicosis.\n\nThe radioactive iodine uptake (RAIU) scan is crucial for determining the cause of thyrotoxicosis.\n- Diffusely increased uptake (45% at 24 hours): This finding indicates that the thyroid gland itself is actively taking up iodine and producing excess hormones. This pattern suggests conditions like Graves' disease or toxic multinodular goiter, where the gland is overactive.\n- Photopenic area corresponding to the nodule: This means the nodule identified on ultrasound does not take up radioactive iodine. A photopenic nodule is also known as a \"cold\" nodule. Cold nodules are typically benign but do not contribute to hormone overproduction.\n\nLet's evaluate the options:\n\nA. Graves' disease with a coexisting cold nodule: Graves' disease is the most common cause of hyperthyroidism and is characterized by diffusely increased radioactive iodine uptake due to stimulation by TSH receptor antibodies. It is common for patients with Graves' disease to have coexisting thyroid nodules, which can be hot, warm, or cold. A cold nodule in the setting of diffuse uptake from Graves' disease is consistent with this diagnosis. The diffuse increased uptake is from the hyperplastic thyroid tissue affected by Graves', and the cold nodule is an incidental finding that is not contributing to the hyperthyroidism.\n\nB. Toxic multinodular goiter: In toxic multinodular goiter (TMNG), hyperthyroidism arises from multiple autonomously functioning nodules. The RAIU scan in TMNG typically shows heterogeneous uptake with areas of increased uptake corresponding to the functioning nodules (\"hot\" nodules) and suppressed uptake in the surrounding, non-functioning normal thyroid tissue. The description of \"diffusely increased uptake\" overall, with a *cold* nodule, is less characteristic of TMNG, which usually presents with patchy uptake localized to the hot nodules.\n\nC. Subacute thyroiditis: Subacute thyroiditis is an inflammatory condition that causes release of pre-formed thyroid hormone. During the hyperthyroid phase of subacute thyroiditis, the thyroid gland is inflamed and unable to trap iodine, leading to a characteristically *low* or suppressed radioactive iodine uptake. This patient's uptake is diffusely *increased*, ruling out subacute thyroiditis.\n\nD. Factitious thyrotoxicosis: This refers to intentional or unintentional ingestion of exogenous thyroid hormone. In this condition, the elevated thyroid hormone levels suppress the pituitary TSH, which in turn reduces the thyroid gland's own production and iodine uptake mechanism. Therefore, the RAIU scan in factitious thyrotoxicosis is typically *low* or suppressed. This patient's uptake is increased, ruling out factitious thyrotoxicosis.\n\nE. Marine-Lenhart syndrome (Graves' disease with a functioning nodule): Marine-Lenhart syndrome is defined as the coexistence of Graves' disease and a solitary, autonomously functioning (hot) nodule. The nodule in this patient's case is *photopenic* (cold), not functioning (hot). Therefore, this diagnosis is incorrect.\n\nBased on the diffusely increased radioactive iodine uptake, indicative of generalized thyroid overactivity, and the presence of a photopenic (cold) nodule, the most likely diagnosis is Graves' disease with a coexisting cold nodule. The hyperthyroidism is explained by the diffuse overactivity of the thyroid gland due to Graves' disease, and the cold nodule is an incidental finding.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-009", "question": "A 50-year-old man with diabetes mellitus and hypertension is found to have a serum potassium of 6.8 mEq/L on routine labs. He is asymptomatic. ECG shows peaked T waves. He is given IV calcium gluconate, insulin/dextrose, and albuterol. His potassium decreases to 6.0 mEq/L. Renal function is normal. Further workup reveals a low serum aldosterone and elevated plasma renin activity. The most likely cause of his hyperkalemia is:", "options": ["Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism)", "Addison's disease", "Gordon's syndrome (pseudohypoaldosteronism type II)", "Spironolactone use", "Rhabdomyolysis"], "answer": "C", "answer_index": 2, "explanation": "Gordon's syndrome (familial hyperkalemic hypertension) is characterized by hyperkalemia, hypertension, normal GFR, metabolic acidosis, and *suppressed* renin but *normal or high* aldosterone. The key here is the elevated renin, which rules out hyporeninemic hypoaldosteronism (A, which has low renin and low aldosterone) and points to a primary renal defect in potassium excretion. Addison's (B) has low aldosterone and high renin but also has hyponatremia and hypotension.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with hyperkalemia (serum potassium of 6.8 mEq/L), peaked T waves on ECG, and normal renal function. His hyperkalemia was partially corrected with IV calcium gluconate, insulin/dextrose, and albuterol, indicating an ongoing physiologic disturbance. Further workup revealed low serum aldosterone and elevated plasma renin activity.\n\nLet's analyze the options:\n\nA. Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism): This condition is characterized by impaired potassium and hydrogen ion excretion by the kidneys, leading to hyperkalemia and metabolic acidosis. The \"hyporeninemic\" part signifies low plasma renin activity (PRA). However, this patient has *elevated* plasma renin activity. Therefore, classic hyporeninemic hypoaldosteronism is unlikely. While Type 4 RTA can be caused by either hyporeninemic hypoaldosteronism or aldosterone resistance, the finding of elevated renin makes the specific descriptor in option A inconsistent with the patient's labs.\n\nB. Addison's disease: This is primary adrenal insufficiency, meaning the adrenal glands fail to produce adequate amounts of steroid hormones, including cortisol and aldosterone. Deficiency of aldosterone leads to impaired sodium reabsorption and potassium excretion, resulting in hyperkalemia. The renin-angiotensin-aldosterone system (RAAS) is activated by the low levels of effective circulating volume and aldosterone, leading to elevated plasma renin activity and angiotensin II. This profile of low serum aldosterone and elevated plasma renin activity perfectly matches the patient's findings and explains his hyperkalemia. Diabetes and hypertension are common comorbidities.\n\nC. Gordon's syndrome (pseudohypoaldosteronism type II): This is a genetic disorder characterized by hypertension, hyperkalemia, and hyperchloremic metabolic acidosis. Paradoxically, it is associated with *elevated* serum aldosterone levels and suppressed plasma renin activity, due to a defect in renal tubule sodium transport sensitivity to aldosterone. This is opposite to the patient's hormonal findings.\n\nD. Spironolactone use: Spironolactone is a potassium-sparing diuretic and an aldosterone antagonist. It blocks the action of aldosterone, leading to hyperkalemia. As a result, the body senses a relative deficiency of aldosterone's effects, and plasma renin activity typically increases. While spironolactone can cause hyperkalemia and elevated renin, serum aldosterone levels can be normal or even high in response to the blockade and compensatory RAAS activation. However, the finding of definitively *low* serum aldosterone, along with elevated renin, is more strongly indicative of primary intrinsic adrenal failure (like Addison's) rather than receptor blockade by a drug, assuming no drug history is provided as an explanation.\n\nE. Rhabdomyolysis: This condition involves muscle breakdown and release of intracellular potassium into the bloodstream, causing hyperkalemia. However, it is not typically associated with specific hormonal changes like low aldosterone and elevated renin. Also, significant rhabdomyolysis substantial enough to cause potassium of 6.8 mEq/L usually presents with muscle pain, weakness, and dark urine; the patient is asymptomatic.\n\nBased on the hormonal findings of low serum aldosterone and elevated plasma renin activity, Addison's disease (primary adrenal insufficiency) is the most likely cause of the patient's hyperkalemia.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-010", "question": "A 65-year-old man with a mechanical aortic valve (On-X) on warfarin presents with a transient ischemic attack. INR on presentation is 1.8 (target 2.5-3.5). He has no bleeding history. The most appropriate adjustment to his antithrombotic regimen is:", "options": ["Increase warfarin dose to achieve INR 2.5-3.5; add aspirin 81 mg daily", "Increase warfarin dose to achieve INR 2.5-3.5; no aspirin needed", "Switch to apixaban 5 mg twice daily", "Add clopidogrel 75 mg daily to current warfarin therapy", "Discontinue warfarin and initiate dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "A", "answer_index": 0, "explanation": "For a mechanical aortic valve, the standard of care is warfarin with a target INR of 2.5-3.5. In patients who have a thromboembolic event despite therapeutic INR, adding aspirin 75-100 mg is recommended. Since his INR was subtherapeutic at the time of the TIA, the first step is to optimize INR control. However, given the event, adding low-dose aspirin is now indicated based on PROACT and other trials. Direct oral anticoagulants (C) are contraindicated in mechanical valves. Dual antiplatelet therapy (E) is inferior to warfarin for valve protection.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has a mechanical aortic valve and is on warfarin, with a target INR of 2.5-3.5. The presence of a mechanical valve necessitates anticoagulation to prevent thromboembolic events. The patient presented with a transient ischemic attack (TIA), which is a thromboembolic event. His current INR is 1.8, which is subtherapeutic for his mechanical valve.\n\nThe most immediate and critical adjustment is to correct the subtherapeutic INR to the target range, as inadequate anticoagulation is the most likely cause for the TIA in this context.\n\nLet's evaluate the options:\n\nA.  Increase warfarin dose to achieve INR 2.5-3.5; add aspirin 81 mg daily: This addresses the subtherapeutic INR, which is crucial. However, adding aspirin to warfarin (dual therapy) significantly increases bleeding risk. While aspirin might be indicated for secondary stroke prevention, it is typically considered after therapeutic anticoagulation is established and after a risk-benefit assessment of adding an antiplatelet agent to warfarin, especially in patients with mechanical valves. It's not always the first or \"most appropriate\" step without further justification.\n\nB.  Increase warfarin dose to achieve INR 2.5-3.5; no aspirin needed: This option directly addresses the primary issue: the subtherapeutic INR. Achieving therapeutic anticoagulation is the most important step to prevent further thromboembolic events. If the TIA was caused by the low INR, correcting it may be sufficient. Adding aspirin is a secondary consideration that increases bleeding risk and may not be necessary. This is a conservative and appropriate first step.\n\nC.  Switch to apixaban 5 mg twice daily: Direct oral anticoagulants (DOACs) such as apixaban are generally not recommended for patients with mechanical heart valves, as they have been associated with a higher risk of thromboembolic events and bleeding compared to warfarin in this specific population.\n\nD.  Add clopidogrel 75 mg daily to current warfarin therapy: Adding a second antithrombotic agent (clopidogrel) to warfarin significantly increases the risk of bleeding. This is typically reserved for specific indications, such as recent stenting of a coronary artery, which is not mentioned in the scenario. The primary problem here is subtherapeutic anticoagulation with warfarin.\n\nE.  Discontinue warfarin and initiate dual antiplatelet therapy with aspirin and clopidogrel: Discontinuing warfarin in a patient with a mechanical aortic valve is generally contraindicated due to the high risk of valve thrombosis and embolization. Dual antiplatelet therapy is not a substitute for anticoagulation in this setting.\n\nComparing options A and B, option B is the most appropriate initial adjustment because it corrects the identified deficiency in the current therapy (subtherapeutic INR) and avoids the increased bleeding risk associated with adding an antiplatelet agent when it may not be immediately necessary. If the TIA recurs despite achieving a therapeutic INR, then adding aspirin or other measures would be reconsidered.\n\nThe final answer is $\\boxed{B}$."}]